期刊文献+

依托泊苷、长春地辛和表阿霉素在输液中的配伍稳定性考察 被引量:5

Compatible stability of etoposide,vindesine and epirubicin for transfusion
原文传递
导出
摘要 目的:考察依托泊苷注射液、注射用长春地辛和注射用表阿霉素在输液中的配伍稳定性,为临床给药提供科学依据。方法:将依托泊苷注射液、注射用长春地辛和注射用表阿霉素在500 mL0.9%氯化钠注射液中配伍,分别考察在25℃和4℃的储存条件下,采用高效液相色谱法测定配伍溶液中依托泊苷、长春地辛和表阿霉素的含量并测定溶液的pH值及不溶性微粒的大小。结果:依托泊苷注射液、注射用长春地辛和注射用表阿霉素在25℃和4℃条件下48 h内配伍液pH值及不溶性微粒无明显变化,含量变化小于5%。结论:在25℃和4℃的储存条件下,3种药物在500 mL的生理盐水中稳定性好,临床上可将3种药物配伍使用。 OBJECTIVE To investigate compatible stability of etoposide,vindesine and epirubicin for transfusion to supply evidence of clinical rational medication.METHODS Changes of pH values and insoluble particles of three drugs were observed after mixed with 500 mL of 0.9% sodium chloride injection and their relative contents were determined by HPLC within 48 h under storage conditions of 25 ℃and4 ℃,respectively.RESULTS No significant changes were noted in pH values and insoluble particles contents of three drugs varied by less than5% within48 h under storage conditions of 25 ℃ and 4 ℃,respectively.CONCLUSION Etoposide,vindesine and epirubicin are stable in 0.9% sodium chloride injection and can be used clinically.
作者 石金芳 豆兴茹 尤晓明 沈国荣 SHI Jin-fang DOU Xing-ru YOU Xiao-ming SHEN Guo-rong(First Affiliated Hospital of Soochow University, Jiangsu Suzhou 215000, China)
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2016年第21期1920-1923,共4页 Chinese Journal of Hospital Pharmacy
基金 苏州市科技发展计划项目(SYSD2015141)
关键词 依托泊苷 长春地辛 表阿霉素 配伍稳定性 etoposide vindesine epirubicin stability
  • 相关文献

参考文献4

二级参考文献29

  • 1徐松林,邓定安,蔡俊超.反相高效液相色谱法测定依普黄酮的含量[J].药物分析杂志,1996,16(2):81-83. 被引量:1
  • 2卫生部药物审评办公室.药物制剂人体生物利用度试验指导原则征求意见稿[J].中国临床药理学杂志,1991,8(3):189-189.
  • 3JOYCE RM,REGAN M,OTTAWAY J,et al.A phase Ⅰ-Ⅱ study of rituximab,ifosfamide,mitoxantrone and etoposide (R-IME) for B cell non-Hodgkin's lymphoma prior to and after high-dose chemotherapy and autologous stem cell transplantation (HDC-ASCT)[J].Ann Oncol,2003,14(1):121-127.
  • 4SLEVIN ML,CLARK PI,JOEL SP,et al.A randomized trial to evaluate the effect schedule on the activity of etoposide in smallcell lung cancer[J].J Clin 0ncol,1989,7(9):1333 -1340.
  • 5MANOUILOV KK,MCGUIRE TR,GORDON BG,et al.Asaay for etoposide in human serum using solid-phase extraction and high-performance liquid chromatography with fluorescence detection[J].J Chromatogr B Biomed Sci Appl,1998,707 (1/2):342-346.
  • 6Korl AD, le Gessie S, Snijder S, et al. Primary extranodal non- Hodgkin' s lymphoma (NHL): the impact of alternative defini- tions tested in the Comprehensive Cancer Centre West popula- tion-based NHL registry. Ann Oncol, 2003, 14:131-139.
  • 7Li XQ, Li GD, Gao ZF, et al. The relative frequencies of lympho- ma subtypes in China: a nationwide study of 10002 cases by the Chinese Lymphoma Study Group. Ann Oncol, 2011, 22 Suppl 4: ivl41.
  • 8Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a stan- dard regimen (CHOP) with three intensive chemotherapy regi- mens for advanced non-Hodgkin' s lymphoma. N Engl J Med, 1993, 328:1002-1006.
  • 9Reyes F, Lepage E, Ganem G, et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med, 2005, 352:1197-1205.
  • 10Coiffier B, Thieblemont C, Van Den Neste E,et ah Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemother- apy in DLBCL patients: a study by the Grouped' Etudes des Lymphomes de 1' Adulte. Blood, 2010, 116:2040-2045.

共引文献261

同被引文献42

引证文献5

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部